caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1124201322

Yudhistira Persaud

PRACTICEBRONXCARE HEALTH SYSTEMSee all providers at this practice →
Allergy/ ImmunologyBronx, NYI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
QUALITY · MIPS · 2024
No data available for this provider in 2024.
FACILITY AFFILIATIONS

Hospital & Facility Affiliations (1)

CCN 330009
Hospital
MEDICARE UTILIZATION · PART B · 2024
No data available for this provider in 2024.
REFERRAL NETWORK

Where Yudhistira Persaud's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 0 inbound referrers · 1 outbound destinations.

Receives referrals from
Inbound — who sends patients here
No inbound pairs above the suppression threshold.
Refers patients to
Outbound — where patients go next
PhysicianPatientsVisits
BRONXCARE DR. MARTIN LUTHER KING JR. HEALTH CENTER4376
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$26K
Payment records
24
By payment type
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$25K
Food and Beverage$1K
PRESCRIBING · PART D · 2024
Total Rx claims
425
Beneficiaries
—
Total drug cost
$489K
Distinct drugs
15
Brand share
59.8%
Top prescribed drugs
Montelukast Sodium52 claims
Albuterol Sulfate50 claims
Dupilumab49 claims
Fluticasone Propionate40 claims
Tezepelumab-Ekko31 claims